IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

NIPPON SHINYAKU CO., LTD.,	
Plaintiff,	
v.	C.A. No. 21-1015 (JLH)
SAREPTA THERAPEUTICS, INC.,	
Defendant.)
SAREPTA THERAPEUTICS, INC. and THE UNIVERSITY OF WESTERN AUSTRALIA,	
Defendant/Counter-Plaintiffs,	
v.))
NIPPON SHINYAKU CO., LTD. and NS PHARMA, INC.)))
Plaintiff/Counter-Defendants.	

SAREPTA THERAPEUTICS, INC. AND THE UNIVERSITY OF WESTERN AUSTRALIA'S MOTION (#3) TO EXCLUDE DR. MICHELLE L. HASTINGS'S OPINIONS AND TESTIMONY CONCERNING ENABLEMENT OF 5'- AND 3'-END MODIFICATIONS

Pursuant to Federal Rule of Evidence 702, Sarepta Therapeutics, Inc. ("Sarepta") and the University of Western Australia ("UWA") respectfully move for the Court to exclude the opinions and testimony of Dr. Michelle L. Hastings concerning enablement of 5'- and 3'-end modifications, which apply the wrong legal standard for enablement, including those contained in Paragraphs 55-60, 65, 75-76, 79, 81, 207, and 209 of her Supplemental Expert Report and Paragraphs 91, 93, 96, 99, and 117 of her Supplemental Reply Expert Report, served on July 3, 2024 and September 4, 2024, respectively. The grounds for this Motion are set forth in the Opening Brief in support thereof, filed concurrently.

Document 609

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Megan E. Dellinger

Jack B. Blumenfeld (#1014) Megan E. Dellinger (#5739) 1201 North Market Street P.O. Box 1347 Wilmington, DE 19899 (302) 658-9200 jblumenfeld@morrisnichols.com mdellinger@morrisnichols.com

Attorneys for Defendant/Counter-Plaintiffs Sarepta Therapeutics, Inc. and The University of Western Australia

OF COUNSEL:

Charles E. Lipsey J. Derek McCorquindale Ryan P. O'Quinn L. Scott Burwell Jameson K. Gardner FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP 1875 Explorer Street, Suite 800 Reston, VA 20190-6023 (571) 203-2700

William B. Raich Michael J. Flibbert John M. Williamson Yoonhee Kim Yoonjin Lee Kaitlyn S. Pehrson FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP 901 New York Avenue, NW Washington, DC 20001-4413 (202) 408-4000

Alissa K. Lipton FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP Two Seaport Lane Boston, MA 02210-2001 (617) 646-1600

Amanda P. Reeves
Anna M. Rathbun
Graham B. Haviland
Michael A. Morin
David P. Frazier
Rebecca L. Rabenstein
Bornali Rashmi Borah
LATHAM & WATKINS LLP
555 Eleventh Street, NW, Suite 1000
Washington, D.C. 20004
(202) 637-2200

Ernest Yakob Rachel Renee Blitzer LATHAM & WATKINS LLP 1271 Avenue of the Americas New York, NY 10020 (212) 906-1200

Michele D. Johnson LATHAM & WATKINS LLP 650 Town Center Drive, 20th Floor Costa Mesa, CA 92626 (714) 540-1235

Will Orlady LATHAM & WATKINS LLP 10250 Constellation Blvd., Suite 1100 Los Angeles, CA 90067 (424) 653-5500

October 2, 2024

RULE 7.1.1 CERTIFICATE

I hereby certify that the subject of the foregoing motion has been discussed with counsel for the plaintiff/counter-defendants and that we have not been able to reach agreement.

/s/ Megan E. Dellinger

Megan E. Dellinger (#5739)

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

NIPPON SHINYAKU CO., LTD.,)
Plaintiff,)
v.) C.A. No. 21-1015 (JLH)
SAREPTA THERAPEUTICS, INC.,))
Defendant.))
SAREPTA THERAPEUTICS, INC. and THE UNIVERSITY OF WESTERN AUSTRALIA,)))
Defendant/Counter-Plaintiffs,))
v.))
NIPPON SHINYAKU CO., LTD. and NS PHARMA, INC.)))
Plaintiff/Counter-Defendants.)

[PROPOSED] ORDER GRANTING SAREPTA THERAPEUTICS, INC. AND THE UNIVERSITY OF WESTERN AUSTRALIA'S MOTION (#3) TO EXCLUDE DR. MICHELLE L. HASTINGS'S OPINIONS AND TESTIMONY CONCERNING ENABLEMENT OF 5'- AND 3'-END MODIFICATIONS

Having considered Sarepta Therapeutics, Inc. ("Sarepta") and the University of Western Australia ("UWA's") motion to exclude Dr. Michelle L. Hastings's opinions and testimony concerning enablement of 5'- and 3'-end modifications, and all related papers filed in connection therewith,

IT IS HEREBY ORDERED that Sarepta and UWA's Motion is GRANTED: the opinions and testimony of Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s expert Dr. Michelle L. Hastings concerning enablement of 5'- and 3'-end modifications, which apply the wrong legal standard for enablement, including those contained in Paragraphs 55-60, 65, 75-76,

79, 81, 207, and 209 of her Supplemental Expert Report and Paragraphs 91, 93, 96, 99, and 117 of her Supplemental Reply Expert Report, served on July 3, 2024 and September 4, 2024, respectively, are hereby excluded.

IT IS SO ORDERED, thisday of	, 2024.
	The Honorable Jennifer L. Hall
	U.S. District Court Judge

CERTIFICATE OF SERVICE

I hereby certify that on October 2, 2024, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on October 2, 2024, upon the following in the manner indicated:

Amy M. Dudash, Esquire MORGAN, LEWIS & BOCKIUS LLP 1201 North Market Street, Suite 2201 Wilmington, DE 19801 Attorneys for Plaintiff

VIA ELECTRONIC MAIL

VIA ELECTRONIC MAIL

Amanda S. Williamson, Esquire Christopher J. Betti, Esquire Krista Vink Venegas, Esquire

Maria E. Doukas, Esquire

Michael T. Sikora, Esquire

Zachary Miller, Esquire

Wan-Shon Lo, Esquire Jason C. White, Esquire

MORGAN, LEWIS & BOCKIUS LLP

110 North Wacker Drive, Suite 2800

Chicago, IL 60606

Attorneys for Plaintiff

Attorneys for Plaintiff

Alison P. Patitucci, Esquire MORGAN, LEWIS & BOCKIUS LLP 1701 Market Street Philadelphia, PA 19103

VIA ELECTRONIC MAIL

Jitsuro Morishita, Esquire MORGAN, LEWIS & BOCKIUS LLP 16F, Marunouchi Building, 2-4-1 Marunouchi, Chiyoda-ku Tokyo, 100-6316 Japan Attorneys for Plaintiff

VIA ELECTRONIC MAIL

David L. Schrader, Esquire MORGAN, LEWIS & BOCKIUS LLP 300 South Grand Avenue, 22nd Floor Los Angeles, CA 90071-3132 Attorneys for Plaintiff VIA ELECTRONIC MAIL

/s/Megan E. Dellinger

Megan E. Dellinger (#5739)